IMMUNOHISTOCHEMISTRY, CYTOKERATIN 19

The IHC – Cytokeratin 19 (CK19) test is an immunohistochemistry-based diagnostic assay used to detect Cytokeratin 19 protein expression in tissue samples. CK19 is the smallest member of the cytokeratin family and is commonly found in the epithelial cells of various organs, including the thyroid gland, pancreas, liver, biliary tract, and gastrointestinal system.

This test is widely used in pathology to identify and classify epithelial tumors and is particularly valuable in the diagnosis of papillary thyroid carcinoma. CK19 expression helps pathologists distinguish malignant lesions from benign conditions and supports accurate tumor classification.

Benefits of the Test

• Helps diagnose epithelial-origin cancers
• Assists in identifying papillary thyroid carcinoma
• Supports tumor classification and differentiation
• Helps distinguish benign from malignant lesions
• Improves diagnostic accuracy and treatment planning

Why Doctors Recommend This Test

Doctors recommend the IHC CK19 test when there is suspicion of thyroid cancer or epithelial malignancies. It is commonly used in:

• Diagnosis of papillary thyroid carcinoma
• Evaluation of thyroid nodules and tumors
• Assessment of pancreatic and biliary tract cancers
• Classification of epithelial neoplasms
• Oncology biopsy interpretation

CK19 is often used alongside markers such as HBME-1, Galectin-3, TTF-1, Thyroglobulin, CK7, and EMA to improve diagnostic accuracy and determine tumor origin.

Preparation Before Test

No special preparation is required for this test. Important considerations include:

• The test is performed on a biopsy or surgical tissue sample
• No fasting or medication restrictions are needed
• Clinical history, imaging findings, and pathology reports may assist interpretation

Normal Reporting Time

The typical turnaround time is 3 to 5 working days, depending on specimen processing and laboratory workflow.

Who Should Take This Test

• Patients with suspected thyroid cancer
• Individuals with thyroid nodules requiring evaluation
• Cases of epithelial tumors with uncertain diagnosis
• Patients undergoing pancreatic or biliary tumor assessment
• Oncology patients requiring immunohistochemistry profiling

The IHC CK19 test is an important diagnostic tool in endocrine pathology and oncology. By identifying Cytokeratin 19 expression in tissue samples, it helps clinicians accurately diagnose epithelial tumors and develop effective treatment strategies.

Clinical Significance

CK19 staining is commonly used in the diagnosis and evaluation of:

• Papillary thyroid carcinoma
• Thyroid epithelial tumors
• Cholangiocarcinoma (bile duct cancer)
• Pancreatic adenocarcinoma
• Hepatobiliary tumors
• Metastatic epithelial malignancies

CK19 is particularly valuable when used as part of a panel of markers to improve the diagnostic accuracy of thyroid cancer evaluation.